The Latest Analyst Ratings for Blueprint Medicines
Portfolio Pulse from Benzinga Insights
Blueprint Medicines (NASDAQ:BPMC) received a mix of analyst ratings in the last quarter, with 2 bullish, 1 somewhat bullish, and 2 indifferent ratings. The average 12-month price target from 5 analysts is $73.00, with a high of $85.00 and a low of $58.00. This target is a 28.07% increase from the previous target of $57.00. Analyst ratings are based on information from company events, financial statements, and insider conversations, and they provide guidance on stock performance.
December 11, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blueprint Medicines has received mixed analyst ratings but a positive average price target increase to $73.00, suggesting a bullish outlook from analysts.
The increase in the average price target for BPMC suggests that analysts have a positive outlook on the stock, which could lead to a short-term increase in its price. The mix of ratings indicates some caution, but the overall sentiment is positive, which is likely to influence investor perception and potentially the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100